Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-15-000759
Filing Date
2015-02-13
Accepted
2015-02-13 17:19:37
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G schedule13gajkazimi2014.htm SC 13G 76168
  Complete submission text file 0001628280-15-000759.txt   77663
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filed by) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 15616336
SIC: 2834 Pharmaceutical Preparations